[go: up one dir, main page]

MA35451B1 - Dérivés de pyrrolopyrimidine et de purine - Google Patents

Dérivés de pyrrolopyrimidine et de purine

Info

Publication number
MA35451B1
MA35451B1 MA36848A MA36848A MA35451B1 MA 35451 B1 MA35451 B1 MA 35451B1 MA 36848 A MA36848 A MA 36848A MA 36848 A MA36848 A MA 36848A MA 35451 B1 MA35451 B1 MA 35451B1
Authority
MA
Morocco
Prior art keywords
pyrrolopyrimidine
purine derivatives
formula
purine
derivatives
Prior art date
Application number
MA36848A
Other languages
English (en)
Inventor
Hengmiao Cheng
Theodore Otto Johnson Jr
John Charles Kath
Kevin Kun-Chin Liu
Elizabeth Ann Lunney
Asako Nagata
Sajiv Krishnan Nair
Simon Paul Planken
Scott Channing Sutton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35451(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA35451B1 publication Critical patent/MA35451B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés représentés par la formule (i) ou des sels pharmaceutiquement acceptables de ces composés. Dans la formule, q, t, v, w, x, y, z, le cycle a, r
MA36848A 2011-09-22 2014-03-21 Dérivés de pyrrolopyrimidine et de purine MA35451B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538103P 2011-09-22 2011-09-22
US201261639639P 2012-04-27 2012-04-27
PCT/IB2012/054702 WO2013042006A1 (fr) 2011-09-22 2012-09-10 Dérivés de pyrrolopyrimidine et de purine

Publications (1)

Publication Number Publication Date
MA35451B1 true MA35451B1 (fr) 2014-09-01

Family

ID=47116127

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36848A MA35451B1 (fr) 2011-09-22 2014-03-21 Dérivés de pyrrolopyrimidine et de purine

Country Status (29)

Country Link
US (2) US9040547B2 (fr)
EP (1) EP2758402B9 (fr)
JP (1) JP5914667B2 (fr)
KR (1) KR20140059246A (fr)
CN (1) CN103814030A (fr)
AP (1) AP2014007475A0 (fr)
AR (1) AR088760A1 (fr)
AU (1) AU2012311184A1 (fr)
BR (1) BR112014006840A2 (fr)
CA (1) CA2847540C (fr)
CL (2) CL2014002726A1 (fr)
CO (1) CO6910196A2 (fr)
CR (1) CR20140132A (fr)
DO (1) DOP2014000055A (fr)
EA (1) EA201490673A1 (fr)
ES (1) ES2575710T3 (fr)
IL (1) IL231592A0 (fr)
MA (1) MA35451B1 (fr)
MD (1) MD20140023A2 (fr)
MX (1) MX2014003501A (fr)
NI (1) NI201400023A (fr)
PE (1) PE20141228A1 (fr)
PH (1) PH12014500638A1 (fr)
SG (1) SG2014014450A (fr)
TN (1) TN2014000115A1 (fr)
TW (1) TWI492946B (fr)
UA (1) UA110259C2 (fr)
UY (1) UY34342A (fr)
WO (1) WO2013042006A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2571361A4 (fr) 2010-05-19 2013-11-13 Univ North Carolina Composés de pyrazolopyrimidine pour le traitement du cancer
LT2585470T (lt) * 2010-06-23 2017-04-10 Hanmi Science Co., Ltd. Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui
EP2704572B1 (fr) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
KR102063098B1 (ko) 2011-10-03 2020-01-08 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암 치료를 위한 피롤로피리미딘 화합물
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CN104302627A (zh) 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 用于治疗癌症的嘧啶化合物
WO2014062774A1 (fr) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Composés pyrazolopyrimidines pour le traitement du cancer
EP2925752A4 (fr) 2012-11-27 2016-06-01 Univ North Carolina Composés à base de pyrimidine utilisables à des fins de traitement du cancer
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
BR112015023020A2 (pt) * 2013-03-14 2017-07-18 Pfizer combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
CA2924362C (fr) * 2013-09-18 2018-12-18 Beijing Hanmi Pharmaceutical Co., Ltd. Compose inhibiteur d'activites de kinase de btk et/ou de jak3
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CA2937431A1 (fr) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Composes
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
CN106458914B (zh) * 2014-03-28 2020-01-14 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物
WO2015157123A1 (fr) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Composés de pyrrolopyrimidine spécifiques de mertk
JP6427599B2 (ja) * 2014-05-19 2018-11-21 チャンスー ヘンルイ メディシン カンパニー，リミテッド チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物
NZ629796A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (fr) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Méthodes de traitement d'un cancer à l'aide de composés de pyrrolopyrimidine substitués, compositions de ceux-ci
CN105524068B (zh) 2014-09-30 2017-11-24 上海海雁医药科技有限公司 氮杂双环衍生物、其制法与医药上的用途
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1244278B (zh) 2015-03-20 2020-04-17 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
AU2016243529B2 (en) * 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106236060B (zh) 2015-06-04 2021-04-09 松下知识产权经营株式会社 生物体信息检测装置
WO2017087905A1 (fr) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Composés, compositions, et procédés
CN108495563B (zh) * 2015-11-25 2022-04-26 R.J.雷诺兹烟草公司 烟碱盐、共晶体和盐共晶体配合物
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN109311857B (zh) 2016-06-16 2021-11-12 戴纳立制药公司 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑
CN114795151A (zh) 2016-06-30 2022-07-29 松下知识产权经营株式会社 方法及系统
EP3587422A4 (fr) * 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation Composé dérivé de pyrrolo-pyrimidine, son procédé de préparation, et composition pharmaceutique comprenant ledit composé en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la protéine kinase
KR102398659B1 (ko) * 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
US10807951B2 (en) 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
CA3083583A1 (fr) * 2017-12-05 2019-06-13 Oscotec Inc. Derive de pyrrolo(pyrazolo)pyrimidine utilise en tant qu'inhibiteur de lrrk2
MX2020006799A (es) 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
KR102577241B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
KR102377007B1 (ko) * 2018-09-20 2022-03-22 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체
EP3842435A4 (fr) * 2018-09-20 2022-05-11 Hanmi Pharm. Co., Ltd. Nouveau dérivé de sulfonamide présentant un squelette de pyrimidine fusionné, ayant un effet inhibiteur de mutation du récepteur du facteur de croissance épidermique
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN115244055B (zh) * 2020-01-21 2024-09-03 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
CN115023428B (zh) * 2020-01-21 2025-04-08 江苏先声药业有限公司 嘧啶并吡咯类化合物
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838B (zh) * 2020-09-30 2024-09-03 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114907357A (zh) * 2021-02-07 2022-08-16 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023041071A1 (fr) * 2021-09-18 2023-03-23 山东新时代药业有限公司 Inhibiteur de l'egfr, son procédé de préparation et son utilisation

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
EP0912559B1 (fr) 1996-07-13 2002-11-06 Glaxo Group Limited Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998002437A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0923585B1 (fr) 1996-07-18 2002-05-08 Pfizer Inc. Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
EP0950059B1 (fr) 1997-01-06 2004-08-04 Pfizer Inc. Derives de sulfone cyclique
ATE248812T1 (de) 1997-02-03 2003-09-15 Pfizer Prod Inc Arylsulfonylhydroxamsäurederivate
CA2279863A1 (fr) 1997-02-07 1998-08-13 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
TR199901926T2 (xx) 1997-02-11 1999-12-21 Pfizer Inc. Arils�lfonil hidroksamik asit t�revleri
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
CA2291709A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
WO1999010349A1 (fr) 1997-08-22 1999-03-04 Zeneca Limited Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
ID23978A (id) 1997-11-11 2000-06-14 Pfizer Prod Inc Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
CO5031249A1 (es) 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
ES2246829T3 (es) 1999-02-01 2006-03-01 Cv Therapeutics Inc Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina.
BR0111548A (pt) 2000-06-22 2003-05-06 Pfizer Prod Inc Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
SG144146A1 (en) 2004-03-05 2008-07-29 Cambridge Biotechnology Ltd Adenosine receptor agonists
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
GB0502573D0 (en) 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0604944D0 (en) * 2006-03-11 2006-04-19 Vernalis R&D Ltd Pyrrolopyrimidine compounds
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
KR20090112732A (ko) 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
UA93609C2 (en) * 2007-02-06 2011-02-25 Пфайзер Инк. 2-amino-5,6-dihydro-6h-pyrrolo[3, 4-d]pyrimidine derivatives as hsp-90 inhibitors for treating cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009026107A1 (fr) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Inhibiteurs de protéine kinases
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010075282A1 (fr) 2008-12-22 2010-07-01 University Of Washington Inhibiteurs moléculaires de la voie wnt/bêta-caténine
WO2010111406A2 (fr) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Composés et leurs utilisations thérapeutiques
WO2010118367A2 (fr) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
WO2011079231A1 (fr) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Composés qui modulent l'activité egfr et des procédés pour traiter ou prévenir des affections avec ceux-ci
WO2011140338A1 (fr) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Composés modulant l'activité des récepteurs egfr et méthodes pour traiter ou prévenir des troubles à l'aide de ceux-ci
CA2813571A1 (fr) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Analogues d'acide 2-(9h-purin-9-yl)acetique substitues en tant qu'inhibiteurs de stat3
WO2012009258A2 (fr) 2010-07-13 2012-01-19 Edward Roberts Modulateurs des récepteurs à la galanine peptidomimétiques
AU2011336764B2 (en) 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
JP2014531449A (ja) * 2011-09-20 2014-11-27 セルゾーム リミティッド キナーゼ阻害剤としてのピラゾロ［４，３―ｃ］ピリジン誘導体
US9881309B2 (en) 2012-03-13 2018-01-30 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
BR112015023020A2 (pt) 2013-03-14 2017-07-18 Pfizer combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
PE20141228A1 (es) 2014-10-01
US9040547B2 (en) 2015-05-26
NI201400023A (es) 2014-10-01
CA2847540A1 (fr) 2013-03-28
TW201313723A (zh) 2013-04-01
UY34342A (es) 2013-04-30
MX2014003501A (es) 2014-07-22
EP2758402A1 (fr) 2014-07-30
TWI492946B (zh) 2015-07-21
EP2758402B9 (fr) 2016-09-14
ES2575710T3 (es) 2016-06-30
AP2014007475A0 (en) 2014-02-28
WO2013042006A1 (fr) 2013-03-28
CL2014000566A1 (es) 2014-10-10
SG2014014450A (en) 2014-09-26
AR088760A1 (es) 2014-07-02
TN2014000115A1 (fr) 2015-07-01
CA2847540C (fr) 2016-05-17
US20130079324A1 (en) 2013-03-28
CR20140132A (es) 2014-05-16
ES2575710T9 (es) 2016-10-17
EA201490673A1 (ru) 2014-06-30
PH12014500638A1 (en) 2017-08-09
BR112014006840A2 (pt) 2017-04-04
CN103814030A (zh) 2014-05-21
IL231592A0 (en) 2014-05-28
JP5914667B2 (ja) 2016-05-11
JP2014526549A (ja) 2014-10-06
UA110259C2 (uk) 2015-12-10
EP2758402B1 (fr) 2016-04-27
CO6910196A2 (es) 2014-03-31
DOP2014000055A (es) 2014-05-15
MD20140023A2 (ro) 2014-06-30
KR20140059246A (ko) 2014-05-15
US20150203502A1 (en) 2015-07-23
AU2012311184A1 (en) 2014-03-06
CL2014002726A1 (es) 2015-02-13

Similar Documents

Publication Publication Date Title
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
MA35841B1 (fr) Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci
PH12015501412A1 (en) SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EA201070786A1 (ru) Бензофуропиримидиноны
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
BRPI0821255A2 (pt) Derivados de espiroindolinona
EA201790923A1 (ru) Производные бетулина
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
EA201100503A1 (ru) Глюкозидные производные и их применения
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX337396B (es) Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
CA2817362C (fr) Composes lipoyles et leur utilisation pour le traitement d'une lesion ischemique
IN2012DN00765A (fr)
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
UA104420C2 (uk) Застосування похідних глутарової кислоти або їх фармацевтично прийнятних солей як протиаритмічних засобів
PH12015501146A1 (en) Hydantoin derivative
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos